← Back to Search

SMART Interventions for Opioid Use Disorder

N/A

Waitlist Available

Research Sponsored by Karen Derefinko, PhD

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Must not have

Under 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 8 months

Awards & highlights

No Placebo-Only Group

Summary

This trial will compare the effectiveness of two different interventions for helping people stick to their medication-assisted treatment for substance abuse.

Who is the study for?

This trial is for adults with Opioid Use Disorder who are eligible to receive buprenorphine-naloxone medication, as determined by the study doctor. Participants must have access to a telephone and be able to understand spoken English.

What is being tested?

The SMART Trial is testing two interventions aimed at improving adherence to medication-assisted treatment: Contingency Management (CM), which rewards patients for meeting certain goals, and a combination of Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM).

What are the potential side effects?

While specific side effects are not listed for the interventions being tested in this trial, common side effects associated with buprenorphine-naloxone include nausea, headache, dizziness, drowsiness, constipation, and sweating.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am younger than 18 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 8 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 8 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 8 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Medication-Assisted Treatment (MAT) Adherence

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Active Control

Group I: Contingency Management (CM)Active Control1 Intervention

CM is a behavioral method that employs external rewards for target behavior. Participants will receive gift cards for adhering to treatment (attending physician visits and being adherent to buprenorphine-naloxone) for their first 4 clinic visits.

Group II: Brief Motivational Interviewing + Substance Free Activities + Mindfulness (BSM)Active Control1 Intervention

Participants will receive the BSM intervention at 4 timepoints.

Group III: BSM+CMActive Control2 Interventions

BSM+CM is a combination of the two other arms. Participants may be randomized to this arm only in stage 2 of the SMART design.

0 / 1Eligibility criteria met